Oramed Pharmaceuticals Inc.
NASDAQ Capital MarketTotal Valuation
Oramed Pharmaceuticals Inc. carries a market capitalization of 183.76M, placing it among publicly traded companies globally. Its enterprise value stands at 148.84M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 183.76M |
| Enterprise Value | 148.84M |
Share Statistics
Oramed Pharmaceuticals Inc. currently has 41.31M shares outstanding.
| Shares Outstanding | 41.31M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Oramed Pharmaceuticals Inc. trades at a trailing price-to-earnings ratio of 1.13.
| PE Ratio | 1.13 |
| PS Ratio | N/A |
| PB Ratio | 0.63 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | -62.33 |
| P/OCF Ratio | -38.06 |
Financial Position
Oramed Pharmaceuticals Inc. maintains a current ratio of 4.98, meaning it holds 5.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.98 |
| Quick Ratio | 4.77 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | N/A |
Financial Efficiency
Oramed Pharmaceuticals Inc. posts a return on equity of 74.10 and a return on invested capital of -4.81.
| Return on Equity (ROE) | 74.10 |
| Return on Assets (ROA) | 65.82 |
| Return on Invested Capital (ROIC) | -4.81 |
| Return on Capital Employed (ROCE) | 73.99 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Oramed Pharmaceuticals Inc. has paid 45.41M in income taxes, reflecting an effective tax rate of 20.62.
| Income Tax | 45.41M |
| Effective Tax Rate | 20.62 |
Stock Price Statistics
Oramed Pharmaceuticals Inc.'s stock has gained approximately 84.01639% over the past 52 weeks. The 50-day moving average sits at 4.62, while the 200-day moving average is 3.92.
| Beta (5Y) | N/A |
| 52-Week Price Change | 84.01639% |
| 50-Day Moving Average | 4.62 |
| 200-Day Moving Average | 3.92 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -14.40M, while operating income came in at -14.52M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -14.52M |
| Pretax Income | 220.28M |
| Net Income | 174.87M |
| EBITDA | -14.40M |
| EBIT | -14.52M |
| Earnings Per Share (EPS) | 4.12 |
Balance Sheet
Oramed Pharmaceuticals Inc. holds 50.61M in cash and equivalents against 733,000.00 in total debt, resulting in a net debt position of -15.24M. Total book value stands at 317.47M, with working capital of 42.68M providing operational flexibility.
| Cash & Cash Equivalents | 50.61M |
| Total Debt | 733,000.00 |
| Net Debt | -15.24M |
| Equity (Book Value) | 317.47M |
| Book Value Per Share | 7.68 |
| Working Capital | 42.68M |
Cash Flow
Oramed Pharmaceuticals Inc. produced -5.21M in operating cash flow over the past twelve months. After subtracting -1.93M in capital expenditures, free cash flow totaled -7.14M - equivalent to -0.17 per share.
| Operating Cash Flow | -5.21M |
| Capital Expenditures | -1.93M |
| Free Cash Flow | -7.14M |
| FCF Per Share | -0.17 |
Dividends & Yields
The company's payout ratio of 5.97 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.25 |
| Dividend Yield | N/A |
| Payout Ratio | 5.97 |
| Shareholder Yield | 8.40 |
| FCF Yield | -1.60 |
Stock Splits
Oramed Pharmaceuticals Inc.'s most recent stock split took place on January 23, 2013 with a 12:1 split ratio.
| Last Split Date | 1/23/2013 |
| Split Ratio | 12:1 |
Scores
Oramed Pharmaceuticals Inc. posts an Altman Z-Score of 2.27, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.27 |